JP2016501013A5 - - Google Patents

Download PDF

Info

Publication number
JP2016501013A5
JP2016501013A5 JP2015541144A JP2015541144A JP2016501013A5 JP 2016501013 A5 JP2016501013 A5 JP 2016501013A5 JP 2015541144 A JP2015541144 A JP 2015541144A JP 2015541144 A JP2015541144 A JP 2015541144A JP 2016501013 A5 JP2016501013 A5 JP 2016501013A5
Authority
JP
Japan
Prior art keywords
cell
vitro
cell activator
γδt
activator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015541144A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501013A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/073328 external-priority patent/WO2014072446A1/en
Publication of JP2016501013A publication Critical patent/JP2016501013A/ja
Publication of JP2016501013A5 publication Critical patent/JP2016501013A5/ja
Pending legal-status Critical Current

Links

JP2015541144A 2012-11-08 2013-11-08 γδＴ細胞の無ＩＬ−２増殖を誘導するための方法 Pending JP2016501013A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306385 2012-11-08
EP12306385.1 2012-11-08
PCT/EP2013/073328 WO2014072446A1 (en) 2012-11-08 2013-11-08 Method for inducing il-2-free proliferation of gamma delta t cells

Publications (2)

Publication Number Publication Date
JP2016501013A JP2016501013A (ja) 2016-01-18
JP2016501013A5 true JP2016501013A5 (enExample) 2016-12-28

Family

ID=47189860

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015541144A Pending JP2016501013A (ja) 2012-11-08 2013-11-08 γδＴ細胞の無ＩＬ−２増殖を誘導するための方法

Country Status (4)

Country Link
US (1) US20150259645A1 (enExample)
EP (1) EP2916858A1 (enExample)
JP (1) JP2016501013A (enExample)
WO (1) WO2014072446A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3218515B1 (en) 2014-11-10 2023-04-26 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for il-33-mediated disorders
CA2960297A1 (en) 2014-11-10 2016-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
IL297773B2 (en) 2014-11-17 2024-07-01 Adicet Bio Inc Engineered gamma delta t-cells
WO2016090250A1 (en) * 2014-12-04 2016-06-09 The University Of North Carolina At Chapel Hill Compositions and methods for preventing and treating graft versus host disease
AU2017261804A1 (en) * 2016-05-12 2018-11-29 Adicet Therapeutics, Inc. Methods for selective expansion of γδ T-cell populations and compositions thereof
US10758591B2 (en) 2016-07-26 2020-09-01 University Of Virginia Patent Foundation Compositions and methods for treating clostridium difficile infection
CN108310367A (zh) * 2017-01-18 2018-07-24 复旦大学 白介素33（il-33）在制备抗乙型肝炎病毒制剂中的用途
AU2018268087B2 (en) * 2017-05-18 2022-03-17 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies
AU2018370120C1 (en) 2017-11-15 2024-05-30 Adicet Therapeutics, Inc. Methods for selective expansion of d3 yd T-cell populations and compositions thereof
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
WO2020065584A1 (en) * 2018-09-27 2020-04-02 Phosphogam, Inc. Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells
CN109517793B (zh) * 2018-11-30 2022-05-10 广州长峰生物技术有限公司 一种NK细胞和γδT细胞共培养的建立方法
EP3890757A1 (en) * 2018-12-03 2021-10-13 Adicet Bio Inc. Methods for selective in vivo expansion of gamma delta t-cell populations and compositions thereof
CA3174680A1 (en) 2020-03-13 2021-09-16 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
EP4426334A4 (en) * 2021-11-04 2025-08-06 Memorial Sloan Kettering Cancer Center IL33 PROTEINS AND METHODS OF USE
WO2023132926A2 (en) * 2022-01-04 2023-07-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compositions and methods for treating cancer
JPWO2023176896A1 (enExample) * 2022-03-18 2023-09-21

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2782721B1 (fr) * 1998-09-01 2000-11-03 Inst Nat Sante Rech Med Nouveaux composes phosphohalohydrines, procede de fabrication et applications
DE60233576D1 (de) * 2002-12-02 2009-10-15 Innate Pharma Interleukin-2 und Gamma Delta T Zellaktivator enthaltende Zusammensetzungen und deren Verwendungen
EP1720567A2 (en) * 2004-02-10 2006-11-15 Innate Pharma Composition and method for the treatment of carcinoma
ITRM20070437A1 (it) * 2007-08-10 2009-02-11 Istituto Naz Per Le Malattie I Metodo per la generazione ed espansione di cellule t gamma/delta regolatorie cellule cosi' ottenute e loro impieghi
JP2010004853A (ja) * 2008-06-30 2010-01-14 Japan Health Science Foundation 制御性ｔ細胞の製造方法

Similar Documents

Publication Publication Date Title
JP2016501013A5 (enExample)
JP2017524031A5 (enExample)
WO2016070166A3 (en) Messenger una molecules and uses thereof
HK1203489A1 (en) Purinone compounds as kinase inhibitors
EA201401281A1 (ru) D-аминокислотные химические соединения для лечения заболеваний печени
WO2015031771A3 (en) Administration of kynurenine depleting enzymes for tumor therapy
WO2015048689A8 (en) Inhibitors of bruton's tyrosine kinase
BR112014018524A2 (pt) derivados de pirimido [4,5-b]indol e métodos de utilização dos mesmos na expansão de células-tronco hematopoiéticas, composição farmacêutica e kits
MX2009006786A (es) Composiciones y metodos para el tratamiento de infecciones y tumores.
NZ609201A (en) Means and methods for treating dlbcl
CO7350624A2 (es) Inhibidores de la tirosina-quinasa de bruton
WO2015035136A3 (en) Delivery system for functional nucleases
BR112015022625A8 (pt) microarranjo para entrega de agente terapêutico e métodos de utilização
BR112015014751A2 (pt) anticorpos anti-tau humanos
WO2018005521A3 (en) Cell culture chambers and methods of use thereof
MD20140035A2 (ro) Metodă de tratament al hepatitei virale C
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
EP2743266A4 (en) PROTEIN KINASE INHIBITORS (VARIANTS), THEIR USE FOR THE TREATMENT OF ONCOLOGICAL DISEASES AND PHARMACEUTICAL COMPOSITION BASED THEREFROM
JP2014087372A5 (enExample)
ES2723827T3 (es) Terapia de combinación de fármacos para el tratamiento de tumores sólidos
EP3826624A4 (en) USE OF ANTI-CD2 ANTIBODY (ADC) DRUG CONJUGATE IN ALLOGENIC CELL THERAPY
CO2020007601A2 (es) Cepa vacunal de brucella modificada para el tratamiento de brucelosis
BR112013033544A2 (pt) dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos
EA032977B1 (ru) Генетически стабильный онколитический рнк вирус, способ его производства и применения
HK1219962A1 (zh) 人抗白细胞介素-32抗体